


**Product Name** : RG7834  
**Cat. No.** : PC-72258  
**CAS No.** : 2072057-17-9  
**Molecular Formula** : C<sub>22</sub>H<sub>27</sub>NO<sub>6</sub>  
**Molecular Weight** : 401.46  
**Target** : HBV  
**Solubility** : 10 mM in DMSO



## Biological Activity

RG7834 (RG-7834, RO7020322) is a potent, specific, orally bioavailable small molecule inhibitor of **HBV** gene expression, reduces HBV total mRNA levels with EC<sub>50</sub> of 5.87 nM.

RG7834 is highly selective for HBV and unlike current therapy inhibits the expression of viral proteins by specifically reducing HBV mRNAs.

RG7834 inhibited HBV genotypes with similar activity, reducing HBV DNA levels with EC<sub>50</sub> of 2.2-6.0 nM, in primary human hepatocytes (PHH) infected with clinical isolates representing the most prevalent HBV genotypes A, B, C, and D.

RG7834 does not interfere with the functions or expression levels of major transcription factors in hepatocytes.

RG7834 reduced HBsAg levels and other viral markers in HBV-infected human liver chimeric uPA-SCID mice.

Combination treatment with RG7834 and entecavir or interferon induced a balanced and profound reduction of both viremia and HBsAg levels.

## References

JD, et al. *J Hepatol.* 2018 Mar;68(3):412-420.

Han X, et al. *J Med Chem.* 2018 Dec 13;61(23):10619-10634.

Mueller H, et al. *Hepatology.* 2019 Apr;69(4):1398-1411.

Sun L, et al. *Antimicrob Agents Chemother.* 2020 Dec 16;65(1):e00640-20.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com